GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Effective Interest Rate on Debt %

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Effective Interest Rate on Debt % : 31.72% (As of Sep. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Navidea Biopharmaceuticals's annualized positive value of Interest Expense for the quarter that ended in Sep. 2023 was $0.41 Mil. Navidea Biopharmaceuticals's average total debt for the quarter that ended in Sep. 2023 was $1.30 Mil. Therefore, Navidea Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 was 31.72%.


Navidea Biopharmaceuticals Effective Interest Rate on Debt % Historical Data

The historical data trend for Navidea Biopharmaceuticals's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Effective Interest Rate on Debt % Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.57 - - 0.58 68.95

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 230.08 46.24 44.26 - 31.72

Competitive Comparison of Navidea Biopharmaceuticals's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Effective Interest Rate on Debt % falls into.



Navidea Biopharmaceuticals Effective Interest Rate on Debt % Calculation

Navidea Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2021 )+Total Debt  (A: Dec. 2022 ))/ count )
=-1  *  -1.098/( (0.749+2.436)/ 2 )
=-1  *  -1.098/1.5925
=68.95 %

where

Total Debt  (A: Dec. 2021 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.02 + 0.729
=0.749

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.873 + 0.563
=2.436

Navidea Biopharmaceuticals's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Sep. 2023 ))/ count )
=-1  *  -0.412/( (1.339+1.259)/ 2 )
=-1  *  -0.412/1.299
=31.72 %

where

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.001 + 1.338
=1.339

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Navidea Biopharmaceuticals Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552